Kiadis Pharma NV (XAMS:KDS) Interest Expense : €-2.04 Mil (TTM As of Dec. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kiadis Pharma NV's interest expense for the six months ended in Dec. 2020 was € -0.91 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2020 was €-2.04 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kiadis Pharma NV's Operating Income for the six months ended in Dec. 2020 was € -14.24 Mil. Kiadis Pharma NV's Interest Expense for the six months ended in Dec. 2020 was € -0.91 Mil. Kiadis Pharma NV did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kiadis Pharma NV Interest Expense Historical Data

The historical data trend for Kiadis Pharma NV's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Interest Expense Chart

Kiadis Pharma NV Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Interest Expense

Get a 7-Day Free Trial

-1.57

-2.29

-4.30

-4.01

-2.04

Kiadis Pharma NV Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
Interest Expense	Get a 7-Day Free Trial											-2.31	-2.21	-1.80	-1.13	-0.91

Kiadis Pharma NV Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2020 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.04 Mil.

Kiadis Pharma NV (XAMS:KDS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kiadis Pharma NV's Interest Expense for the six months ended in Dec. 2020 was €-0.91 Mil. Its Operating Income for the six months ended in Dec. 2020 was €-14.24 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2020 was €5.37 Mil.

Kiadis Pharma NV's Interest Coverage for the quarter that ended in Dec. 2020 is calculated as

Kiadis Pharma NV did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Kiadis Pharma NV (XAMS:KDS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP

Website

https://www.kiadis.com

Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines